Hypera S.A.
Recent
price
P/E
ratio
div
yld
4.20%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hypera S.A. (HYPE3.SA) operates as one of Brazil's largest pharmaceutical companies, focusing on the development, manufacturing, and distribution of a diverse portfolio of prescription and non-prescription medicines, dermocosmetics, nutraceuticals, generics, similars, and institutional products. The company leads the Brazilian market in over-the-counter (OTC) medicines with iconic brands including Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina; in the prescription segment under the Mantecorp Farmasa umbrella, it offers products such as Addera D3, Nesina, Dramin, Alivium, Predsim, Lisador, and Rinosoro across primary care therapeutic classes; Neo Química provides generics and similars; Mantecorp Skincare, Simple Organic, and Bioage deliver dermocosmetics, organic vegan skincare, and professional aesthetic treatments; and the non-retail institutional market includes injectables like Bac-Sulfitrin, Buscopan, Dramin, Hyfol (propofol), and the biological Hyblut for thrombosis and embolism treatment, alongside nutraceuticals such as Tamarine, Biotônico Fontoura, and Zero-Cal. Hypera maintains a broad national sales and distribution network across Brazil, with emerging presence in Latin America including Mexico, Argentina, Colombia, and Chile through acquired portfolios, supported by its large-scale production complex in Anápolis, Goiás—the largest in Latin America—and the Hynova research center for innovation in medicines, dermocosmetics, and nutraceuticals. Founded in 2001 as Hypermarcas and renamed Hypera Pharma in 2017 to emphasize its pharmaceutical focus, the company is headquartered in São Paulo, Brazil, lists on B3's Novo Mercado segment since 2008, and employs approximately 10,000 people. Recent developments include a July 2025 shareholder agreement forming a new controlling group holding 53% of share capital, involving entities such as João Alves de Queiroz Filho, Loriem S.A. de C.V., and Votorantim S.A., pending CADE antitrust approval; strong Q3 2025 revenue growth of 16% to BRL 2.2 billion driven by retail sell-out in flu, respiratory, antiallergics, and painkillers, with ongoing expansion into private institutional markets, oncology, biologics, and semaglutide projects; prior acquisitions such as Takeda's portfolio (Neosaldina, Dramin, Nesina) in 2021, Sanofi's OTC and prescription drugs (AAS, Naturetti, Cepacol) in 2022, Boehringer Ingelheim's Buscopan family and production assets in 2020-2022, and Bioage in 2021; and launches of line extensions in skincare sun protection, moisturizing, anti-aging, and an innovation pipeline exceeding 500 products.
Company News
Lyra Therapeutics (OTCMKTS:LYRA) versus Hypermarcas (OTCMKTS:HYPMY) Head-To-Head Analysis
Hypermarcas (OTCMKTS:HYPMY) Reaches New 12-Month High – Should You Buy?
Hypermarcas (OTCMKTS:HYPMY) Stock Price Up 8% – Should You Buy?
Contrasting Hypermarcas (OTCMKTS:HYPMY) and Ensysce Biosciences (NASDAQ:ENSC)
Hypermarcas (OTCMKTS:HYPMY) Shares Pass Below Two Hundred Day Moving Average – Here’s What Happened
Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
Hypermarcas (OTCMKTS:HYPMY) Sees Large Increase in Short Interest
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
Hypermarcas (OTCMKTS:HYPMY) Shares Gap Up – Here’s What Happened
Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript
Brazil's Hypera announces new majority stakeholder group
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Hypera: Short-Term Pain For Long-Term Gain
Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio